DDInter852 DDInter1435
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Halofantrine {u} (Compound) resembles {v} (Compound) Lumefantrine
Halofantrine {u} (Compound) binds {v} (Gene) CYP2C8
Halofantrine {u} (Compound) upregulates {v} (Gene) HMOX1
Halofantrine {u} (Compound) downregulates {v} (Gene) CDC20
Halofantrine {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Halofantrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Halofantrine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Halofantrine {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Halofantrine (Compound) resembles Lumefantrine (Compound)
Halofantrine (Compound) binds CYP2C8 (Gene)
Halofantrine (Compound) upregulates HMOX1 (Gene)
Halofantrine (Compound) downregulates CDC20 (Gene)
Halofantrine (Compound) causes Gastrointestinal pain (Side Effect)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Halofantrine may lead to a major life threatening interaction when taken with Dasatinib
Halofantrine may lead to a major life threatening interaction when taken with Amiodarone